NYMXFOTCIn Vitro & In Vivo Diagnostic SubstancesUS GAAP · USD

Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corp. is a biopharmaceutical company focused on developing and seeking regulatory approval for therapeutic products for benign prostatic hyperplasia (BPH) and early prostate cancer. The company is based in Nassau, The Bahamas, and serves the U.S. and international drug development and commercialization market through its proprietary prostate-treatment programs.

Ask about the company
Net income-4.3m USD
+4.8 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-15-10-505m USD2020: 0.01 m USD2020: EBIT -12 m USD20202021: 0.00 m USD2021: EBIT -13 m USD20212022: 0.00 m USD2022: EBIT -6.7 m USD20222023: 0.00 m USD2023: EBIT -8.4 m USD20232024: 0.00 m USD2024: EBIT -4.3 m USD20242025
RevenueOperating profit (EBIT)
Ask Clarifo about Nymox Pharmaceutical Corp

Business

Share of revenue
Prostate therapeutics85 %

Drug candidates and development programs aimed at treating BPH and related prostate conditions.

Regulatory submissions15 %

Preparation and resubmission activities supporting marketing approval for the company's lead program.

Customers

Nymox's direct customers are primarily regulators, physicians, and future patients rather than broad commercial buyers, because the business is centered on drug development and approval. Its end market is men affected by BPH and early prostate cancer, with clinical and regulatory stakeholders determining whether the products can reach patients. In a development-stage model, demand is driven by unmet medical need and physician adoption once approval is obtained.

Regulatory agencies

Review clinical dossiers and marketing applications for approval to sell the company's therapy.

Urologists and physicians

Would prescribe the treatment if approved, based on safety and efficacy profile.

BPH patients

Men seeking treatment for benign prostatic hyperplasia, especially those concerned about side effects.

Early prostate cancer patients

A potential treated population for the company's prostate-focused drug program.

Potential licensing or commercial partners

May support development, commercialization, or distribution if the program advances.

Strategy

The company's strategy is centered on advancing its lead prostate therapy through updated dossiers and renewed regulatory submissions, particularly in the United States. It is also trying to preserve optionality around commercialization by strengthening the clinical and regulatory package for a treatment aimed at an area of persistent unmet need. Because the business depends heavily on a single lead program, execution on filings and data support is central to its strategy.

Regulatory resubmission of NYMOZARFEXShort term

Approval is the key gating item for any commercial value creation.

Evidence generation and dossier qualityShort term

Stronger clinical support improves the chance of review and approval.

Commercial optionality for prostate indicationsMedium term

The company wants a pathway to market if the therapy is approved.

Geography

Nymox is incorporated and headquartered in Nassau, The Bahamas, but its development and regulatory focus is centered on the United States. The company also references worldwide BPH demand, so its commercial opportunity is not limited to one country if approval is obtained. Geography matters mainly because drug approval, clinical development, and eventual commercialization are governed by national regulators and market access rules.

Risks

Nymox faces substantial regulatory and development risk because its value depends on successful drug approval, and its initial U.S. submission was not accepted for review. The company also has concentration risk in a single lead product, making outcomes highly sensitive to clinical data, filing quality, and financing availability. As with most biotech developers, timelines can be long, outcomes uncertain, and commercialization dependent on external regulators and future capital.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →U.S. regulatory non-acceptance or delay1Dependence on a single lead asset2Financing risk3Clinical development uncertainty4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. U.S. regulatory non-acceptance or delayImpact: CriticalLikelihood: High

    The company's initial U.S. submission was not accepted for review, showing filing risk.

    Exposure: Lead prostate therapy approval pathway

  2. Dependence on a single lead assetImpact: HighLikelihood: High

    Most of the company's value is tied to NYMOZARFEX/Fexapotide.

    Exposure: Prostate therapeutics pipeline

  3. Financing riskImpact: HighLikelihood: High

    Further resubmissions require additional financing according to company disclosures.

    Exposure: Clinical and regulatory execution

  4. Clinical development uncertaintyImpact: HighLikelihood: Medium

    Drug approval depends on interpretation of efficacy, safety, and statistical evidence.

    Exposure: Phase 3 and supporting data

Ask Clarifo about Nymox Pharmaceutical Corp

Accounting

Judgemental items
Research and development expense

Clinical and regulatory work is the core cost base and is typically expensed as incurred.

Impact: Drives reported operating losses and cash burn

Impairment and recoverability

Lead-program value may need reassessment if approval paths weaken or timelines slip.

Impact: Could affect asset carrying values and earnings

Going-concern and financing disclosures

Further submissions require financing, making liquidity assumptions important.

Impact: Affects investor perception of solvency and continuity

Similar listed companies

Publicly listed companies with a comparable business focus.

Nuvectis Pharma, Inc.

NVCT · Pharmaceutical Preparations

Kymera Therapeutics, Inc.

KYMR · Biological Products, (No Diagnostic Substances)

Biomea Fusion, Inc.

BMEA · Pharmaceutical Preparations

Agentix Corp.

AGTX · Biological Products, (No Diagnostic Substances)

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

Neumora Therapeutics, Inc.

NMRA · Biological Products, (No Diagnostic Substances)

Last updated: 28/09/2026